Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23360896 | 0.81 | FFAR1 (0.40) | ROCK2SCDNR1H2USP30FFAR1 | |
| SCHEMBL141413 | 0.81 | FFAR1 (0.52) | ROCK2SCDNR1H2USP30FFAR1 | |
| SCHEMBL722900 | 0.81 | ROCK2 (0.39) | ROCK2SCDNR1H2USP30GPR119 | |
| SCHEMBL13006087 | 0.76 | FFAR1 (0.36) | FFAR1 | |
| SCHEMBL23349424 | 0.76 | SCD (0.38) | ROCK2SCDNR1H2USP30FFAR1 | |
| SCHEMBL25826104 | 0.76 | FFAR1 (0.44) | ROCK2SCDNR1H2USP30FFAR1 | |
| SCHEMBL19341509 | 0.76 | FFAR1 (0.44) | ROCK2SCDNR1H2USP30FFAR1 | |
| SCHEMBL19964091 | 0.75 | FFAR1 (0.40) | ROCK2SCDNR1H2USP30FFAR1 | |
| SCHEMBL20922047 | 0.74 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL20733996 | 0.74 | FFAR1 (0.45) | ROCK2SCDNR1H2USP30FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | ROCK2 3506/4885SCD 3453/4885NR1H2 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.